TME Pharma N.V. (ALTME) - Net Assets
Based on the latest financial reports, TME Pharma N.V. (ALTME) has net assets worth €-570.00K EUR (≈ $-666.39K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.29 Million ≈ $2.68 Million USD) and total liabilities (€2.86 Million ≈ $3.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TME Pharma N.V. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-570.00K |
| % of Total Assets | -24.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | -79.03% |
| 10-Year Change | N/A |
| Growth Volatility | 43.37 |
TME Pharma N.V. - Net Assets Trend (2014–2024)
This chart illustrates how TME Pharma N.V.'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of TME Pharma N.V. for the complete picture of this company's asset base.
Annual Net Assets for TME Pharma N.V. (2014–2024)
The table below shows the annual net assets of TME Pharma N.V. from 2014 to 2024. For live valuation and market cap data, see TME Pharma N.V. (ALTME) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.61 Million ≈ $1.89 Million |
+648.98% |
| 2023-12-31 | €-294.00K ≈ $-343.72K |
+76.89% |
| 2022-12-31 | €-1.27 Million ≈ $-1.49 Million |
-128.25% |
| 2021-12-31 | €4.50 Million ≈ $5.26 Million |
-41.52% |
| 2020-12-31 | €7.70 Million ≈ $9.00 Million |
+515.21% |
| 2019-12-31 | €-1.85 Million ≈ $-2.17 Million |
+28.88% |
| 2018-12-31 | €-2.61 Million ≈ $-3.05 Million |
+33.48% |
| 2017-12-31 | €-3.92 Million ≈ $-4.58 Million |
-57.90% |
| 2016-12-31 | €-2.48 Million ≈ $-2.90 Million |
+64.70% |
| 2015-12-31 | €-7.03 Million ≈ $-8.22 Million |
-12.64% |
| 2014-12-31 | €-6.24 Million ≈ $-7.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to TME Pharma N.V.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9780700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €942.00K | 58.36% |
| Other Comprehensive Income | €10.00K | 0.62% |
| Other Components | €200.76 Million | 12438.35% |
| Total Equity | €1.61 Million | 100.00% |
TME Pharma N.V. Competitors by Market Cap
The table below lists competitors of TME Pharma N.V. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BPH Energy Ltd
AU:BPH
|
$7.66 Million |
|
Ssif Broker Cl
RO:BRK
|
$7.67 Million |
|
Red Sky Energy Ltd
AU:ROG
|
$7.67 Million |
|
Conquest Resources Ltd
V:CQR
|
$7.68 Million |
|
Iron Road Ltd
AU:IRD
|
$7.65 Million |
|
Thor Energy Plc
AU:THR
|
$7.65 Million |
|
Kiora Pharmaceuticals Inc
NASDAQ:KPRX
|
$7.65 Million |
|
Equity Story Group Ltd
AU:EQS
|
$7.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TME Pharma N.V.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -294,000 to 1,614,000, a change of 1,908,000.
- Net loss of 5,722,000 reduced equity.
- Share repurchases of 2,000 reduced equity.
- New share issuances of 7,281,000 increased equity.
- Other comprehensive income increased equity by 4,000.
- Other factors increased equity by 347,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-5.72 Million | -354.52% |
| Share Repurchases | €2.00K | -0.12% |
| Share Issuances | €7.28 Million | +451.12% |
| Other Comprehensive Income | €4.00K | +0.25% |
| Other Changes | €347.00K | +21.5% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares TME Pharma N.V.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | €-403.37 | €0.08 | x |
| 2015-12-31 | €-645.08 | €0.08 | x |
| 2016-12-31 | €-154.78 | €0.08 | x |
| 2017-12-31 | €-184.22 | €0.08 | x |
| 2018-12-31 | €-65.24 | €0.08 | x |
| 2019-12-31 | €-14.97 | €0.08 | x |
| 2020-12-31 | €21.60 | €0.08 | x |
| 2021-12-31 | €6.84 | €0.08 | x |
| 2022-12-31 | €-1.08 | €0.08 | x |
| 2023-12-31 | €-0.06 | €0.08 | x |
| 2024-12-31 | €0.06 | €0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TME Pharma N.V. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -354.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30115.79%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 2.11x
- Recent ROE (-354.52%) is below the historical average (-73.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -55192.00% | 0.01x | 0.00x | €-13.17 Million |
| 2015 | 0.00% | -37446.51% | 0.01x | 0.00x | €-15.40 Million |
| 2016 | 0.00% | -12948.19% | 0.03x | 0.00x | €-10.50 Million |
| 2017 | 0.00% | -2301.28% | 0.25x | 0.00x | €-4.99 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | €-10.47 Million |
| 2019 | 0.00% | -559090.91% | 0.00x | 0.00x | €-676.70K |
| 2020 | -134.95% | -29728571.43% | 0.00x | 1.38x | €-11.18 Million |
| 2021 | -320.09% | -43793.94% | 0.00x | 2.16x | €-14.90 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-15.00 Million |
| 2023 | 0.00% | -39623.53% | 0.01x | 0.00x | €-6.71 Million |
| 2024 | -354.52% | -30115.79% | 0.01x | 2.11x | €-5.88 Million |
Industry Comparison
This section compares TME Pharma N.V.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $32,053,695
- Average return on equity (ROE) among peers: -506.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TME Pharma N.V. (ALTME) | €-570.00K | 0.00% | N/A | $7.66 Million |
| Abionyx Pharma SA (ABNX) | $10.68 Million | -54.53% | 1.04x | $123.48 Million |
| Abivax SA (ABVX) | $4.67 Million | -803.57% | 14.26x | $6.97 Billion |
| Adocia (ADOC) | $6.02 Million | 0.00% | 0.61x | $107.24 Million |
| Aelis Farma SA (AELIS) | $2.38 Million | -114.51% | 1.64x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $-1.13 Million | 0.00% | 0.00x | $866.09K |
| Cellectis (ALCLS) | $285.90 Million | -34.76% | 0.16x | $269.37 Million |
| Advicenne (ALDVI) | $309.00K | -4021.68% | 60.10x | $20.79 Million |
| Genoway (ALGEN) | $9.00 Million | -7.64% | 2.06x | $30.11 Million |
| Integragen (ALINT) | $3.76 Million | -27.74% | 1.44x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-1.06 Million | 0.00% | 0.00x | $1.80 Million |
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more